Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026

Keyword: Pathophysiology

Publisher: PRNewswire

Published: Jun 24, 2026

Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the invest… [+15599 chars]

Read Full Story ↗